|1.||Schulz, Jörg B: 3 articles (11/2015 - 03/2012)|
|2.||Mariotti, Caterina: 3 articles (11/2015 - 03/2012)|
|3.||Pandolfo, Massimo: 3 articles (11/2015 - 03/2012)|
|4.||Klockgether, Thomas: 3 articles (11/2015 - 03/2012)|
|5.||Giunti, Paola: 3 articles (11/2015 - 03/2012)|
|6.||Boesch, Sylvia: 3 articles (11/2015 - 03/2012)|
|7.||Schöls, Ludger: 3 articles (11/2015 - 03/2012)|
|8.||Timmann, D: 3 articles (06/2013 - 09/2008)|
|9.||Melegh, B: 3 articles (06/2013 - 09/2008)|
|10.||Fancellu, R: 3 articles (06/2013 - 09/2008)|
06/01/2013 - "The present analysis and published data from the EUROSCA natural history study suggest that INAS is a valid measure of extracerebellar involvement in progressive ataxia disorders. "
11/01/2015 - "The primary outcome was the scale for the assessment and rating of ataxia (SARA), and the inventory of non-ataxia signs (INAS). "
01/01/2015 - "Semiquantitative analysis of ataxia-associated symptoms was performed using Scale for the Assessment and Rating of Ataxia (SARA) and the Brief Ataxia Rating Scale (BARS) scores, while extracerebellar features were measured employing the Inventory of Non-ataxia Symptoms (INAS) scale. "
06/01/2013 - "Therefore we devised the Inventory of Non-Ataxia Signs (INAS), a list of neurological signs that allows determining the presence and severity of non-ataxia signs in a standardized way. "
06/01/2013 - "Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument."
|2.||Spinocerebellar Ataxias (Spinocerebellar Ataxia)
06/01/2013 - "INAS underwent a rigorous validation procedure that involved a trial of 140 patients with spinocerebellar ataxia (SCA) for testing of inter-rater reliability and another trial of 28 SCA patients to assess short-term intra-rater reliability. "
02/01/2015 - "The primary outcome measure was the Scale for the Assessment and Rating of Ataxia (SARA) and secondary outcome measures were the Inventory of Non-Ataxia Signs (INAS), the performance-based coordination test Spinocerebellar Ataxia Functional Index (SCAFI), the neurocognitive phonemic verbal fluency test, and two quality-of-life measures: the activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale and EQ-5D. "
08/07/2005 - "The present studies examined whether these effects were associated with the development of compound-specific proteinuria after 10 or 30 days following subcutaneous injection of GaAs or InAs particles in hamsters. "
08/07/2005 - "These changes were associated with GaAs and InAs proteinuria patterns as monitored by two-dimensional gel electrophoresis and silver staining. "
01/07/2015 - "Misfit dislocation free InAs/GaSb core-shell nanowires grown by molecular beam epitaxy."
01/01/2013 - "The atomic arrangements of two types of InAs dislocation cores associated by a Z-shape faulted dipole are observed directly by aberration-corrected high-angle annular-dark-field imaging. "
01/01/2013 - "Atomic configurations at InAs partial dislocation cores associated with Z-shape faulted dipoles."
01/01/2012 - "The dislocations were trapped within a thin InAs epilayer. "
01/01/2012 - "Dislocation reduction of InAs nanofins prepared on Si substrate using metal-organic vapor-phase epitaxy."
01/01/2014 - "The present survey indicated that InAs from rice and hijiki consumption contributed to total daily InAs intake and consequently to significant cancer risk of the general Japanese population. "
08/01/2012 - "Cancer risk posed by the dietary InAs of the general Japanese may not be negligible."
08/01/2012 - "On the basis of InAs intakes estimated and the oral slope factor of the US EPA and Health Canada, excess cancer risk was estimated to exceed acceptable level. "
02/01/2013 - "This feature makes INAs and their synthetic analogues useful as adjuvants in vaccines and in cancer treatment. "
01/04/2010 - "The biodistribution of INAs in nude mice bearing tumor implied that this PSD-based nanoassembly loading PS/DNA could be a promising gene delivery system for tumor therapy."
|3.||Ethylene Glycol (Monoethylene Glycol)
|5.||Biological Markers (Surrogate Marker)
|2.||Quantum Dots (Quantum Dot)
|4.||Drug Therapy (Chemotherapy)
|5.||Activities of Daily Living (ADL)